Evoke Reports Positive Results from Phase 2b Study of Metoclopramide Nasal Spray for Gastroparesis in Diabetics

Evoke Pharma (Nasdaq: EVOK ) today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide. See full press release (c) 2014 Benzinga.com. Benzinga does